Figure 1.
Rates of severe IDIN in patients treated with deferiprone across the clinical-development program. Stratification of rates of severe IDIN from clinical trials or postmarketing setting by discrete ANC groups based on the nadir ANC: group 1, ANC 0.2 × 109/L to 0.5 × 109/L; group 2, ANC 0.1 × 109/L to 0.199 × 109/L; or group 3, ANC <0.1 × 109/L. Rates of severe IDIN were normalized to estimated deferiprone exposure and expressed as the number of severe IDIN events per 100 patient-years.
